Compare EUDA & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | PLUR |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | Singapore | Israel |
| Employees | 123 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 25.5M |
| IPO Year | N/A | 2001 |
| Metric | EUDA | PLUR |
|---|---|---|
| Price | $13.62 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $55.00 | $12.00 |
| AVG Volume (30 Days) | 2.3K | ★ 37.2K |
| Earning Date | 12-19-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | $134.73 | $97.38 |
| Revenue Next Year | $195.03 | $293.97 |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.33 | $1.56 |
| 52 Week High | $25.70 | $5.68 |
| Indicator | EUDA | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 35.72 |
| Support Level | $1.20 | N/A |
| Resistance Level | $15.36 | $2.50 |
| Average True Range (ATR) | 0.85 | 0.17 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 46.50 | 21.68 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.